Nektar Therapeutics

Howard Robin joined Nektar Therapeutics in January 2007. He has more than 25 years of successful biopharmaceutical experience managing clinical development and commercial operations. Most recently, Mr. Robin served as President and Chief Executive Officer of Sirna Therapeutics, a clinical-stage biotechnology company pioneering RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration (AMD), hepatitis C, asthma, respiratory syncytial virus (RSV) and Huntington's disease. During his tenure at Sirna, Mr. Robin successfully re-launched the company and created significant shareholder value that led to its acquisition by Merck for $1.1 billion. Prior to Sirna, Mr. Robin spent 20 years at Berlex Laboratories, the U.S. pharmaceutical subsidiary of the German pharmaceutical firm Schering AG. From 1991 to 2001, he served as corporate vice president and general manager of their U.S. Therapeutics division and was responsible for the development of drugs, such as Betaseron® (Interferon beta-1b) for multiple sclerosis and Fludara® (fludarabine phosphate) for chronic lymphocytic leukemia, generating annual global sales in excess of $800 million. He also served as a member of the Executive Committee. Prior to that, he was vice president of Finance and Business Development and CFO of Berlex. Earlier in his career, Mr. Robin was a senior associate with Arthur Andersen and Co. Mr. Robin holds a B.S. in Accounting and Finance from Fairleigh Dickinson University in New Jersey.

Bharatt Chowrira, Ph.D., J.D. joined the Company as Chief Operating Officer in May 2008. His responsibilities include overseeing and managing all research and manufacturing operations across the Company, as well as corporate functions including business development, licensing and marketing. He will also serve as Chairman of Nektar India Pvt., Ltd. Dr. Chowrira had previously served as Executive Director, Worldwide Licensing & External Research at Merck & Co. in San Francisco. He was responsible for identifying and evaluating R&D, licensing and partnering opportunities across all therapeutics areas, therapeutic modalities (including small molecules, biologics, vaccines and oligonucleotides), and technology platforms, throughout Asia. Dr. Chowrira was a key member of the team that established collaboration agreements between Merck and leading pharmaceutical firms in India such as Nicholas Piramal and Ranbaxy Labs. Dr. Chowrira also served as Vice President of Sirna Therapeutics, a wholly owned subsidiary of Merck, where his responsibilities included strategic planning and licensing. Prior to Merck, Dr. Chowrira was a member of the executive management team at Sirna Therapeutics, a development-stage biopharmaceutical firm focused on the discovery and development of RNAi-based drugs that selectively target disease-causing genes and viruses. As Vice President at Sirna, he played a pivotal role in the restructuring and 2003 relaunch of the company, the development of its pipeline and intellectual property portfolio, and ultimately the sale of Sirna to Merck. He led the effort to identify research opportunities that resulted in corporate collaborations and licensing agreements with all of Sirna's partners, which included industry leaders such as GlaxoSmithKline, Allergan, and Eli Lilly & Co. Dr. Chowrira earned his Ph.D. in Microbiology and Molecular Genetics from the University of Vermont and his J.D. degree from the College of Law at the University of Denver. He earned his M.S. in Molecular Virology from Illinois State University and his B.Sc. in Microbiology from the University of Agricultural Sciences, Bangalore, India.

Jillian B. Thomsen has served as our Vice President Finance and Chief Accounting Officer since April 2008. Ms. Thomsen joined Nektar in March 2006 as our Vice President Finance and Corporate Controller. Before joining Nektar, Ms. Thomsen was Vice President Finance and Deputy Corporate Controller of Calpine Corporation from September 2002 to February 2006. Previously, Ms. Thomsen is a certified public accountant and was a senior manager at Arthur Andersen LLP, where she worked from 1990 to 2002, and specialized in audits of multinational consumer products, life sciences, manufacturing and energy companies. Ms. Thomsen holds a Masters of Accountancy from the University of Denver and a B.A. in Business Economics from Colorado College.

John Nicholson was appointed Senior Vice President and Chief Financial Officer (CFO) of the company in December 2007. Mr. Nicholson reports to Nektar's President and Chief Executive Officer, Howard W. Robin. Previously, Mr. Nicholson was Senior Vice President, Corporate Development and Business Operations at Nektar. Prior to joining Nektar, he served in a number of leadership roles at Bayer Schering Pharma AG, including Vice President, Corporate Development and Treasurer of Schering Berlin Inc., President of Schering Berlin Insurance Company, President of Bayer Pharma Chemicals Inc., and President of Schering Berlin Capital Corporation. Mr. Nicholson also served as Treasurer of Berlex Inc.

John S. Patton, Ph.D. , age 61, our co-founder, has served as our Chief Research Fellow since April 2008, and has served as a director since July 1990. Dr. Patton served as Chief Scientific Officer from December 2001 to March 2008 and Vice President, Research from December 1991 to November 2001. He served as our President from the Company s incorporation in July 1990 to December 1991. From 1985 to 1990, Dr. Patton was a Project Team Leader with Genentech, Inc., a biotechnology company, where he headed their non-invasive drug delivery activities. Dr. Patton was on the faculty of the Marine Science and Microbiology Departments at the University of Georgia from 1979 through 1985, where he was granted tenure in 1984. Dr. Patton received a B.S. in Zoology and Biochemistry from Pennsylvania State University, an M.S. from the University of Rhode Island, a Ph.D. in Biology from the University of California, San Diego and received post doctorate fellowships from Harvard Medical School and the University of Lund, Sweden, both in biomedicine. Dr. Patton is also a director of Halozyme Therapeutics, Inc., a biopharmaceutical company.

Christopher A. Kuebler has served as our director since December 2001. Mr. Kuebler also currently serves on the board of directors of Waters Corporation, an analytical technologies services company. From January 1997 to December 2005, Mr. Kuebler served as Chairman of the Board of Covance Inc., a drug development services company, and from November 1994 to December 2004, served as its Chief Executive Officer. From March 1993 through November 1994, he was the Corporate Vice President, European Operations for Abbott Laboratories Inc., a diversified health care company. From January 1986 until March 1993, Mr. Kuebler served in various commercial positions for Abbott Laboratories' Pharmaceutical Division and was the Division's Vice President, Sales and Marketing prior to taking the position of Corporate Vice President, European Operations. Before that, he held positions at Squibb Inc. and Monsanto Health Care. Mr. Kuebler holds a B.S in Biological Science from Florida State University.

Rinko Ghosh joined Nektar in May 2001 and has more than 17 years of experience in pharmaceutical, biotechnology and related industries. His primary responsibilities at Nektar have included product and technology licensing, mergers and acquisitions, strategic planning, portfolio evaluation and alliance management. At Nektar he has been instrumental in closing large, revenue-generating transactions and building long-term, strategic partnerships with Bayer, Novartis, Baxter, Amgen, Roche, Pfizer, UCB and other major pharmaceutical companies. Prior to joining Nektar, he was engaged as Commercial Development Consultant at Aviron (now MedImmune/Astra Zeneca) in Palo Alto, CA. Before Aviron, he was co-CEO of a biopharmaceutical startup in Asia. Earlier, he spent several years in healthcare and general management consulting at the San Francisco office of A.T. Kearney. Mr. Ghosh has been actively involved with non-profits, including the Asian Art Museum of San Francisco. He has served on several non-profit boards where has helped resolve issues related to board governance, general management and strategic planning. Mr. Ghosh holds an M.B.A. degree from the Wharton School, University of Pennsylvania, an M.S. degree in Environmental Engineering from Vanderbilt University, and a B.S. degree in Chemical Engineering from the Indian Institute of Technology.

Susan Wang has served as our director since December 2003. Ms, Wang, who retired from Solectron in May 2002, served in various management positions there from 1984 to June 2002. Her final position at Solectron, an electronics manufacturing services and supply chain solutions company, was Executive Vice President for Corporate Development and Chief Financial Officer, a position she held from September 2001 to June 2002. Prior to joining Solectron, Ms. Wang held financial and managerial positions with Xerox Corporation and Westvaco Corporation. She began her career with Price Waterhouse & Co. in New York and is a certified public accountant. Ms. Wang is also a director of Altera Corporation, a programmable semiconductor company, and Avanex Corporation, an optical switching company. Ms. Wang earned an M.B.A. from the University of Connecticut and a B.S. in Accounting from the University of Texas.

Susan Wang has served as a member of our Board of Directors since March 2009. Ms. Wang retired from Solectron Corporation in 2002 from her position as Executive Vice President, Corporate Development and Chief Financial Officer. From 2003 to 2008, she served as a director and Chairperson of the Audit Committee and a member of the Executive Committee of Calpine Corporation. She is currently a director and Chairperson of the Audit Committee of Avanex Corporation, Altera Corporation, and Nektar Therapeutics. She also is a member of the Compensation Committee of Avanex Corporation. Ms. Wang is a CPA and holds a Bachelor of Arts degree in Accounting from the University of Texas and an MBA in Finance from the University of Connecticut.

Christopher A. Kuebler has served as our director since December 2001. Mr. Kuebler also currently serves on the board of directors of Waters Corporation, an analytical technologies services company. From January 1997 to December 2005, Mr. Kuebler served as Chairman of the Board of Covance Inc., a drug development services company, and from November 1994 to December 2004, served as its Chief Executive Officer. From March 1993 through November 1994, he was the Corporate Vice President, European Operations for Abbott Laboratories Inc., a diversified health care company. From January 1986 until March 1993, Mr. Kuebler served in various commercial positions for Abbott Laboratories' Pharmaceutical Division and was the Division's Vice President, Sales and Marketing prior to taking the position of Corporate Vice President, European Operations. Before that, he held positions at Squibb Inc. and Monsanto Health Care. Mr. Kuebler holds a B.S in Biological Science from Florida State University.

Hoyoung Huh has served as our director since February 2008. Since March 2008, Dr. Huh has served as President and CEO of BiPar Sciences, a privately held biopharmaceutical company focused on oncology therapeutics. From May 2007 through February 2008, Dr. Huh served as our Chief Operating Officer and Head of the PEGylation Business Unit, responsible for worldwide business development, marketing, manufacturing and leading Nektar's PEGylation business. From March 2005 through April 2007, he served as Senior Vice President of Business Development and Marketing. From September 1997 to February 2005, Dr. Huh was a leader in the healthcare and biotechnology practice at McKinsey and Company, a management consulting firm, where he was elected partner in 2003. He currently serves on the board of BayBio, a biotechnology industry association. Dr. Huh holds an M.D. from Cornell University Medical College, a Ph.D. in Genetics and Cell biology from the Cornell University / Sloan Kettering Institute, and an A.B. in Biochemistry from Dartmouth College.

Lutz Lingnau was appointed director in August 2007. Mr. Lingnau retired from Schering AG Group, Germany, in 2005 as a member of Schering AG's Executive Board and as Vice Chairman, President and Chief Executive Officer of Schering Berlin, Inc., a United States subsidiary. Prior to his retirement, Mr. Lingnau was responsible for Schering AG's worldwide specialized therapeutics and dermatology businesses. He joined Schering AG's business trainee program in 1966. Throughout his career at Schering AG, he served in various capacities and in a number of subsidiaries in South America and the United States, including his roles as President of Bertek, Incorporated, from 1983 to 1985, as the Head of Worldwide Sales and Marketing in the Pharmaceutical Division of Schering AG, from 1985 to 1989, and as Chairman of Berlex Laboratories, Inc. from 1985 to 2005. Mr. Lingnau is currently a member of the Supervisory Board of LANXESS AG, Chairman of the board of directors of Micropharma Limited, a biotechnology company, and was a member of the board of directors of Sirna Therapeutics, inc., a biotechnology company, from February 2006 through the closing of the acquisition of Sirna by Merck & Co., Inc. in December 2006.

Dr. Brown has nearly 30 years experience in the Defense Industry, initially as an Army officer and more recently as a senior analyst and manager at Science Applications International Corporation (SAIC) and Hicks and Associates. During his Army career, Dr. Brown served as an infantry officer with operational assignments in the Berlin Brigade and the 82nd Airborne Division. He was also a faculty member of the Social Sciences Department at the United States Military Academy where he taught courses on international relations theory, international security issues and economics. Later in his military career, Dr. Brown served as a special or military assistant to senior decision makers in the Department of Defense, including the Supreme Allied Commander, Europe (SACEUR), the Assistant Secretary of the Army for Manpower and Reserve Affairs (ASA M&RA), the Army's Chief of Legislative Liaison and the Director of Net Assessment in the Office of the Secretary of Defense. When he came to SAIC, Dr. Brown worked on studies associated with the emerging security environment, the Revolution in Military Affairs information operations, in particular and Military Transformation. He also worked on several classified projects whose goal was understanding the economic dimensions of strategy. Currently, Dr. Brown is a Senior Vice President of Hicks and Associates (a wholly owned subsidiary of SAIC). Prior to this he was Director of the Strategic Assessment Center at H&AI and SAIC. The Strategic Assessment Center conducts studies and analyses of issues associated with strategy, policy and military transformation primarily for clients in the Office of Net Assessment in the Office of the Secretary of Defense, the Intelligence Community, the Experimentation Directorate of the Joint Forces Command, the Concept Development and Experimentation branch of Allied Command Transformation and the individual Services.